The advent of GLP-1 agonists, commonly known as "fat jabs," represents a significant development in the treatment of obesity, a widespread health issue in modern society. While lauded by many as a medical breakthrough on par with penicillin or anesthetics, these drugs, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), also raise concerns reminiscent of past medical treatments that proved to have unforeseen and severe consequences.
These drugs function similarly to a chemical gastric band, suppressing appetite and aiding in weight loss. Initially licensed in the U.S. about a decade ago and more recently in Britain, an estimated 1.6 million people are currently using them, primarily through private prescriptions. The upcoming availability of cheaper, pill-based versions is expected to dramatically increase accessibility.
While oral semaglutide has been available since June, the pill form of tirzepatide, Fouyouo, recently received approval from the UK regulator. These oral versions are anticipated to cost roughly half as much as injectable forms, with monthly costs estimated between £100-£150, making them more attainable for a larger population.
This shift is poised to have far-reaching consequences, impacting the medical profession, healthcare systems, and cultural attitudes toward obesity. However, questions about their safety persist. Historically, numerous treatments marketed as miracle cures have led to disastrous outcomes. Examples include thalidomide, which caused severe birth defects, and mercury, once used to treat syphilis, leading to organ failure and brain damage. The Victorians' use of cocaine and opiates as general remedies and the opioid crisis fueled by painkillers like OxyContin also serve as stark warnings.
In the context of weight-loss drugs, historical parallels include dinitrophenol in the 1930s, a "fat-burning" drug that caused organ failure. Amphetamines in the 1950s and 60s, while suppressing appetite, were highly addictive and linked to cardiovascular damage. The combination drug "fen-phen" in the 1990s was withdrawn due to heart and lung problems, resulting in substantial legal damages. Ephedra, a plant-based supplement popular in the early 2000s, was banned after being linked to heart attacks, strokes, and sudden death. Rimonabant, another weight-loss drug, was associated with severe psychiatric issues.
For GLP-1s, known side effects can include severe pancreatitis and an increased risk of gallstones. Concerns have also been raised about muscle loss and malnutrition. Official figures in Britain have linked over 200 deaths and 158,000 adverse reactions to weight-loss drugs, though regulatory agencies stress these numbers indicate suspected associations rather than proven causation.
Despite these concerns, many physicians maintain that the advantages of GLP-1s outweigh the risks when properly monitored. Large-scale studies suggest these drugs not only aid in weight loss but also improve heart health, reduce fatty liver disease, enhance kidney function, and can help manage sleep apnea. Intriguingly, they have also shown potential in controlling cravings for substances like alcohol, tobacco, and opioids.
The societal impact of these drugs is also notable. They challenge long-standing cultural biases, such as "fat-shaming" and the notion of moral superiority associated with thinness. The "cult of thin" has been described as a tyranny, particularly for women navigating the biological changes of pregnancy, hormonal shifts, and menopause. Economically, the rise of GLP-1s is affecting industries such as second-hand clothing and the diet sector, with some users reporting significant weight loss leading them to sell larger-sized garments. Restaurants, especially fast-food establishments, are also seeing changes, with a notable percentage of GLP-1 users dining out less frequently and ordering smaller portions.
The increased use of these drugs is also influencing the food industry, with a rise in "nutrient-dense" ready meals designed to help users combat potential side effects like hair loss and fatigue by ensuring adequate intake of high-quality protein and essential nutrients.
For some individuals, GLP-1s have been personally transformative, leading to improved weight stability, enhanced self-confidence, better health markers, and improved mental well-being previously affected by weight-related self-loathing. Beyond the aesthetic benefits, users report tangible improvements in quality of life, such as reduced joint pain and increased motivation for physical activity.
While the potential benefits are significant, the historical context of medical innovations warrants caution. The hope is that faith in these new treatments is not misplaced, and that the promise of a healthier lives outweighs the risks, but the underlying concern remains that if something appears too good to be true, it often is.